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able or unresectable HNSCC were treated with ICT TPF90 followed by concurrent chemora-
diotherapy. Forty-four patients (84.6%) received at least three cycles of ICT TPF90. The most
commonly observed Grade 3e4 adverse events included neutropenia (35%), anemia (25%), sto-
matitis (35%), diarrhea (16%), and infections (13.5%). In an intention-to-treat analysis, the
complete and partial response rates after ICT TPF90 were 13.5% and 59.6%, respectively.
The complete and partial response rates following radiotherapy and salvage surgery were
42.3% and 25.0%, respectively. The estimated 3-year overall survival and progression-free sur-
vival rates were 41% [95% confidence interval (CI): 25e56%] and 23% (95% CI: 10e39%), respec-
tively. The observed median overall survival and progression-free survival were 21.0 months
(95% CI: 13.3e28.7 months) and 16.0 months (95% CI: 10.7e21.3 months), respectively.
Conclusion: TPF90 is a suitable option for Asian patients with borderline resectable or unre-
sectable HNSCC who are scheduled for ICT.
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nc-nd/4.0/).Introduction
The combination of radiotherapy (RT) and chemotherapy
(CT) may improve the clinical outcomes of patients with
head and neck squamous cell carcinoma (HNSCC). In this
regard, the meta-analysis of CT in head and neck cancer
demonstrated that concomitant chemoradiotherapy (CCRT)
confers an absolute benefit of 6.5% [hazard ratio, 0.81; 95%
confidence interval (CI), 0.78e0.86; p < 0.001] at 5 years.1
In contrast, induction CT (ICT) schedules do not generally
show any positive impact on overall survival (OS), the only
exception being the combination of cisplatin and 5-
fluorouracil (PF).1 Although Phase III ICT trials in HNSCC
patients reported that a triple regimen comprising doce-
taxel, cisplatin, and 5-fluorouracil (TPF) is superior to PF in
terms of clinical response and survival rates,2e4 randomized
trials do not provide strong support for the use of ICT.5,6 In
this scenario, the potential benefits of ICT in the clinical
management of HNSCC patients remain a matter of debate.
These observations notwithstanding, ICT continues to be
commonly used for HNSCC patients.
In the era of organ-function preservation, the long-term
results of the RTOG 91e11 and GORTEC 2000e01 studies
demonstrated the clinical usefulness of ICT followed by RT in
patients with advanced larynx or hypopharynx squamous cell
carcinomas.7,8 Other potential clinical advantages of ICT
include the following: (1) reduction in symptoms and func-
tional improvement before RT; (2) accelerated tumor
shrinkage that can reduce the need for urgent maneuvers
(e.g., tracheostomy for airway obstruction, tube feeding for
swallowing problems); (3) acting as an effective bridge before
definitive treatment when RT cannot be initiated immedi-
ately; (4) clearance of micrometastases; and (5) in vivo
assessment of treatment response that may guide subsequent
therapeutic interventions. Such potential advantages are
paramount in the clinical management of patients with unre-
sectable HNSCC, for whom ICTmay confer a survival benefit.9
In light of these findings, the Taiwanese National Health In-
surance implemented (as of 2011) a reimbursement program
for ICT TPF performed in patients with unresectable HNSCC.
Unfortunately, ICT TPF can be associated with serious
side effects, including subsequent inability to undergoang H-M, et al., Induction chemot
ctable or unresectable head and
16.03.005definitive therapy and deaths, in a substantial proportion of
patients with advanced HNSCC (especially in those with a
low socioeconomic status and poor general conditions).10
Significant ethnic differences in susceptibility to the
effects of docetaxel exist, with Asian patients having a
19-fold increased risk of docetaxel-induced severe neu-
tropenia compared with non-Asian individuals.11 Conse-
quently, docetaxel dose reduction has been proposed in
Asian HNSCC patients.12,13 Another point that merits
consideration is the high prevalence of betel quid chewing
in the Taiwanese population, with > 80% of HNSCC patients
being betel quid chewers. Notably, the incidence of severe
( Grade 3) mucositis in Taiwanese patients treated with
ICT PF is significantly higher (approx. 40%) than that
observed in Western populations (8e11%),14 possibly
because of betel quid chewing-related mucosa dam-
age.14,15 In this scenario, a dosage adjustment optimization
that can protect against toxicity without reducing the ef-
ficacy of treatment would be of paramount importance. We
therefore presented the safety and efficacy of dose-
modified ICT TPF in Asian patients with borderline resect-
able or unresectable HNSCC.Materials and methods
Patients
TPF was reimbursed for unresectable HNSCC by the Taiwan
National Health Insurance since January 2011. Since then,
patients with biopsy-proven HNSCC judged to be borderline
resectable or unresectable by a multidisciplinary tumor
board were enrolled if their consent to ICT TPF was ob-
tained. All patients were staged according to the American
Joint Committee on Cancer 2010 staging criteria.16 Patients
had to meet the following criteria to receive ICT TPF: (1)
age  70 years; (2) Eastern Cooperative Oncology Group
performance status between 0 and 2; (3) adequate bone
marrow function (leukocyte count  4000/L; platelet
count  100,000/L); and (4) acceptable renal (serum
creatinine < 2.0 mg/dL) and liver (total bilirubin 
1.5  the upper limit of normal; serum glutamicherapy with dose-modified docetaxel, cisplatin, and 5-fluorouracil
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transaminase  2.5  the upper limit of normal) function.
Exclusion criteria were as follows: (1) presence of distant
metastases; (2) previous history of malignancies, CT, or RT;
(3) serious concomitant illness (e.g., liver cirrhosis, angina,
or myocardial disease); and (4) active uncontrolled in-
fections. Written informed consent was obtained from all
the patients before therapy. This retrospective analysis was
approved by the local Institutional Review Board.
Dose-modified TPF regimen
The standard TPF regimen,2 consisting of docetaxel (Sanofi-
Aventis, Paris, France, or TTY BioPharm Co. Ltd., Taipei,
Taiwan) at a dose of 75 mg/m2 given as a 1-hour infusion on
Day 1, followed by cisplatin at a dose of 75 mg/m2 admin-
istered as a 2-hour infusion on Day 1, and 5-fluorouracil at a
dose of 750 mg/m2/d given by continuous infusion on Days
1e5, was used for reimbursed daily practice. However, two
patients experienced neutropenic fever and one patient
had Grade 3 diarrhea in our first six patients who received
the standard TPF dosage. The dosage of TPF was then de-
escalated to 90% of the original TPF dosage (TPF90) (con-
sisting of docetaxel 67.5 mg/m2 on Day 1, cisplatin
67.5 mg/m2 on Day 1, and 5-fluorouracil at a dose of
675 mg/m2/d on Days 1e5) for the following six patients.
One patient experienced two episodes of upper gastroin-
testinal bleeding of unknown cause during the two ICT
TPF90 cycles. No other severe adverse event was observed
in other patients of this cohort. In accordance with the
above observation, TPF90 was recommended for the
following patients who were scheduled to receive ICT TPF.
Treatment design
ICT TPF90 was administered every 3 weeks (defined as 1
cycle) for up to three to four cycles. However, the treat-
ment was stopped in the presence of the following condi-
tions: (1) progressive disease; (2) unacceptable adverse
events occurring during the first or the second cycle; and
(3) withdrawal from the study. Ciprofloxacin prophylaxis
(500 mg orally twice a day) was performed from Day 8 to
Day 14 of each cycle for their possible effect on the
decrement of infection.2,17 Granulocyte colony-stimulating
factor was permitted only in patients with febrile neu-
tropenia or infections. Patients who experienced  Grade 3
neutropenia in previous treatment would receive reduced-
dosage TPF rather than prophylactic granulocyte colony-
stimulating factor.
Patients who received ICT TPF at the recommended
dosage were allowed to delay the next cycle until the
severity of adverse events resolved to  Grade 1. However,
delays of 2 weeks or longer were considered as treatment
discontinuations. Dose modifications in subsequent cycles
were required in presence of Grade 3 toxicity (the only
exceptions being the onset of alopecia, fatigue, malaise,
and nail changes). We planned a 10% parallel dose de-
escalation of each agent at each step of dose modification.
However, we did not perform docetaxel dose reductions
when adverse events were obviously caused by cisplatin
(e.g., nephrotoxicity) or 5-fluorouracil (e.g., mucositis).Please cite this article in press as: Wang H-M, et al., Induction chemot
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TPF dose level was calculated in relation to docetaxel
dosing. Patients who required a dose reduction to less than
80% of the original TPF dosage (TPF80) were withdrawn from
the ICT schedule. Following ICT, patients were scheduled to
receive weekly cisplatin 40 mg/m2 with concurrent RT.
However, the CT regimens could be changed at the physi-
cian’s discretion in patients with disease progression or
poor general conditions because of ICT.
External beam RT (6 MV X-rays) was delivered through
intensity-modulated techniques. Patients received 2.0 Gy/
fraction once daily, 5 fractions per week. The gross target
volume (GTV) was defined according to both nasophar-
yngolaryngoscope and imaging findings (magnetic reso-
nance imaging, computed tomography, and 18F-
fluorodeoxyglucose-positron emission tomography). The
prophylactic clinical target volume was initially designed to
include the neck lymphatics at risk and all the tissue
located within 1 cm of the GTV (dose: 46e50 Gy). Subse-
quently, the radiation field was restricted to the GTV, the
tissue located within 0.5 cm of the GTV, and the grossly
involved nodal area (dose: 70e76 Gy). The maximal dose
allowed for spinal cord and brain stem irradiation was
50e60 Gy. The mean dose for parotid sparing was limited to
23 Gy, whereas uninvolved constrict muscles did not
receive more than 56 Gy whenever possible.
Salvage surgery for resectable residual disease was
performed between 6 weeks and 12 weeks following CCRT
termination. Patients who had N2 or N3 nodal disease at the
initial presentation and showed complete responses to
CCRT did not undergo elective neck dissection.
Tumor clinical assessments were performed every
3 weeks throughout the entire ICT treatment period. Head
and neck imaging (computed tomography or magnetic
resonance imaging) was scheduled: (1) at the end of ICT
TPF; (2) following CCRT; and (3) in patients who showed
disease progression. Post-CCRT monitoring was performed
on a monthly basis during the 1st year, every 2 months
during the 2nd year, every 3 months during the 3rd year, and
every 6 months thereafter (until the date of data censoring
or death).
Statistical analysis
Time-to-event endpoints were calculated from the begin-
ning of ICT TPF90 to the time of death from any cause (OS)
or the time to disease progression, relapse, or death from
any cause (progression-free survival, PFS). All time-to-
event endpoints were analyzed on an intention-to-treat
basis. Time-to-event data were plotted using the
KaplaneMeier method (log-rank test). Adverse events were
analyzed in the safety population who received at least one
ICT TPF90 cycle. All calculations were performed using the
SPSS statistical package, version 18.0 (SPSS Inc., Chicago,
IL, USA). A p value < 0.05 (two tailed) was considered
statistically significant.
Results
Between March 2011 and May 2014, a total of 52 consecu-
tive patients who received ICT TPF90 were examined.herapy with dose-modified docetaxel, cisplatin, and 5-fluorouracil
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least 1 year of follow up for the last patient included in the
study). Table 1 shows the general features of the 52 study
patients. Fifty patients (96.2%) were males, and the most
common primary tumor site was the oropharynx (44.2%).
Forty-six patients (88.5%) had T4 disease and 44 (84.7%)
patients had N2eN3 disease. All the patients had Stage IV
disease. Tumors were deemed to be borderline resectable
and unresectable in 18 (34.6%) and 34 (65.4%) patients,
respectively.
Forty-four patients (84.6%) received at least three cycles
of ICT with modified TPF (TPFm). The remaining patients
received  2 cycles of TPFm for the following reasons:
death from unknown cause (n Z 1), disease progression
(n Z 2), neutropenic fever and fatigue (n Z 1), tumor
bleeding (n Z 1), acute renal failure (n Z 1), severeTable 1 Characteristics of TPF90 intention-to-treat
population.
Characteristics n Percentage
Sex
Male 50 96.2
Female 2 3.8
Age (y)
Median (range) 48 (33e66)
ECOG performance status
0 9 17.3
1 40 76.9
2 3 5.8
Tumor site
Oropharynx cancer 23 44.2
Oral cavity cancer 16 30.8
Hypopharynx cancer 10 19.2
Paranasal sinus cancer 3 5.8
Pathologic differentiation
Well 5 9.6
Moderate 26 50.0
Poor 7 13.5
NA 14 26.9
Tumor status
T1 3 5.8
T2 2 3.8
T3 1 1.9
T4A 24 46.2
T4B 22 42.3
Node status
N0 4 7.7
N1 4 7.7
N2 33 63.5
N3 11 21.2
Stage
IVA 22 42.3
IVB 30 57.7
Resectability
Borderline resectable 18 34.6
Unresectable 34 65.4
ECOG Z Eastern Cooperative Oncology Group; NA Z not
assessed; TPF90 Z 90% dose of the original docetax-
elecisplatinefluorouracil regimen.
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Patients who received at least one cycle of TPF90 were
included in the safety analysis (Table 2). Grade 34 adverse
events, which occurred in at least 10% of the study pa-
tients, were as follows: neutropenia (35%), anemia (25%),
stomatitis (35%), diarrhea (16%), and infections (13.5%).
Five of the seven patients (13.5%) who experienced in-
fections also had neutropenia. One patient who did not
develop any obvious adverse event (as assessed in the pa-
tient’s 1st clinical visit performed after the initial TPF90
cycle) died at home of unknown cause on the 9th day of ICT.
The TPFm cycles were administered at a median interval of
23 days (range: 20e31 days). Treatment delays of  7 days
were identified in 17 patients (32.7%). The reasons for
treatment delays included the occurrence of adverse
events in eight patients (15.4%) and other reasons (mainly
related to administration issues) in the remaining nine pa-
tients (17.3%). Thirteen patients (25%) had their dose
reduced from TPF90 to TPF80 for their second ICT cycle.
Dose reductions were mainly due to the occurrence of
nonhematologic adverse events. Forty-two (80.8%) patients
had either gained weight or maintained their body weight
at the end of ICT.
The intention-to-treat overall response rate (RR) after
ICT TPF90 was 73.1%, with the complete response (CR) and
partial response (PR) rates being 13.5% (7 patients) and
59.6% (31 patients), respectively.
Eight patients (15.4%) did not receive the originally
scheduled RT following ICT TPF90 for the following reasons:
consent withdrawal (n Z 5), suspected lung metastasis
(n Z 1), surgery (n Z 1), and death (n Z 1). Forty-four
patients (84.6%) received post-ICT CCRT. The median time
interval between the finish of the last ICT TPF to the start
of RT was 20.5 days (range, 0e56 days). The CT schemesTable 2 Adverse events observed in the study.
Event/NCI CTCAE 3.0 grading 0 1 2 3 4
During induction chemotherapy (n Z 52; %)
Neutropenia 23 14 28 14 21
Anemia 2 46 27 19 6
Thrombocytopenia 73 27 0 0 0
Vomiting 67 12 12 9 0
Stomatitis 21 6 38 33 2
Diarrhea 42 21 21 16 0
Renal insufficiency 73 15 6 2 4
Liver dysfunction 31 52 11 6 0
During radiotherapy concomitant with cisplatin 40 mg/m2
weekly (n Z 27; %)
Neutropenia 37 18 26 15 4
Anemia 4 26 40 26 4
Thrombocytopenia 18 56 15 11 0
Vomiting 74 11 11 4 0
Stomatitis 0 0 22 63 15
Dermatitis 8 44 33 15 0
Diarrhea 96 4 0 0 0
Renal insufficiency 66 30 4 0 0
Liver dysfunction 70 22 4 4 0
NCI CTCAE 3.0 Z National Cancer Institute Common Terminol-
ogy Criteria for Adverse Events, version 3.0.
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Table 3 Postinduction chemoradiotherapy and the compliance (n Z 44).
Clinical scenario n Drugs during radiotherapy Drugs cycles Radiotherapy > 60 Gy (n)
Per protocol 27 Cisplatin 40 mg/m2/wk 4.5 (median) 26
Fatigue 6 Cisplatin 30 mg/m2/wk 1, 1, 2, 3, 5, 8 6
Renal insufficiency 4 Carboplatin (AUC Z 2)a 2, 2, 5, 6 4
Neuropathy 2 Cetuximabb 5, 8 2
Postsurgery 1 Cetuximabb þ docetaxelc 7 1
Physician’s discretion 4 Othersd 1, 5, 5, 7 4
a Area under curve (AUC) used in the Calvert’s formula to calculate the dose of carboplatin.
b Initial dose of 400 mg/m2followed by subsequent doses of 250 mg/m2/wk.
c Docetaxel 15 mg/m2/wk.
d Others: methotrexate or paclitaxel.
Figure 2 KaplaneMeier plots of progression-free survival
(patients at risk and 95% confidence intervals are depicted).
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The median duration of RT was 52 days (range: 38e75 days)
with a median dosage of 72 Gy (range: 56e80.2 Gy). Only
one patient who died of pneumonia within 30 days of the
end of CCRT received an RT dose of < 60 Gy.
The intention-to-treat overall RR after CCRT was 65.3%.
The CR and PR rates were 28.8% (15 patients) and 36.5% (19
patients), respectively. Seven patients (13.5%) received
salvage surgery for the presence of residual disease (2 pa-
tients at lymph nodes only and 5 patients at both the pri-
mary tumor and the nodes). After salvage surgery, the
intention-to-treat overall RR was 67.3%, with CR and PR
rates being 42.3% (22 patients) and 25.0% (13 patients),
respectively.
In the last survival analysis performed in May 2015, the
median follow-up time of the 21 surviving patients was
34 months. The median OS and PFS durations were 21 months
(95% CI: 14e28 months) and 16 months (95% CI:
11e21months), respectively (Figures 1 and 2). The estimated
3-year OS and PFS rates were 41% (95% CI: 25e56%) and 23%
(95% CI: 10e39%), respectively. Treatment failures occurred
in 34 patients (65%). Initial failures had the following distri-
bution: locoregional failure (nZ 20; 38%); locoregional and
distant failure (nZ 4; 8%); distant failure only (nZ 6; 11%);Figure 1 KaplaneMeier plots of overall survival (patients at
risk and 95% confidence intervals are depicted).
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drawal according to the study protocol (nZ 3; 6%).
Discussion
A proper selection of candidates is paramount to optimize
the success of ICT. In accordance with our treatment
guideline, ICT TPF was specifically focused on patients with
borderline resectable or unresectable HNSCC because they
can potentially benefit from this approach.18 However, the
classification of a tumor as either borderline resectable or
unresectable is not univocal and may be physician depen-
dent. Herein, our multidisciplinary tumor board considered
a tumor as borderline resectable or unresectable when the
following criteria were met: (1) presence of very advanced
local disease according to the American Joint Committee on
Cancer 2010 staging criteria (pharyngeal tumors)16; (2)
tumor invasion occurring above the mandibular notch in
patients with oral cancer19; (3) marked central compart-
ment involvement; and (4) presence of N3 disease. Patients
who met such stringent criteria are deemed to have a poor
prognosis.
Another critical issue is the proper selection of the TPF
regimen. Two different ICT TPF dosages have been reported
in the literature.2,17 The combined regimen of docetaxelherapy with dose-modified docetaxel, cisplatin, and 5-fluorouracil
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fluorouracil 750 mg/m2/d on Days 1e5 was used by the
TAX 323 study group.2 However, the TAX 324 study group
utilized the following scheme: docetaxel 75 mg/m2 on Day
1, cisplatin 100 mg/m2 on Day 1, and 5-fluorouracil
1000 mg/m2/d on Days 1e4.17 As 5-fluorouracil at a dose
of 1000 mg/m2/d has been shown to cause a high incidence
of stomatitis at 96e120 hours of infusion in our pa-
tients,14,15 we selected the TAX 323 trial dosage as the
reference regimen (TPF100). TPF90 was then selected as the
optimal dosage for ICT TPF in our clinical scenario. The
observation that 25% (< 33%) of the treated patients
required a dose reduction from TPF90 to TPF80 during the
second ICT cycle supported the clinical feasibility of TPF90
as an ICT regimen.
The exact number of ICT cycles to be conducted before
locoregional therapy has not been clearly established. In
general, three to four cycles of ICT are required to ensure
optimal clinical results,20 but the total number may vary
according to the RRs and the incidence of adverse events.
Herein, 44 patients (84.6%) received  3 ICT TPFm cycles.
The methodology used in the current study (including the
patient population and the TPF regimen) is similar to that
of the TAX 323 trial.2 The major Grade 3e4 adverse events
observed in our study and in the TAX 323 trial were as fol-
lows: neutropenia 35% versus 77%; anemia 25% versus 9%;
stomatitis 35% versus 5%; diarrhea 16% versus 3%; and in-
fections 13.5% versus 6.9%. Despite a lower incidence of
neutropenia, severe stomatitis and diarrhea occurred at a
relatively high frequency in our patients. As betel quid
chewing-related changes in the oral mucosa cannot easily
explain these observations, we believe that they may be
dependent on ethnic or genetic factors that warrant further
scrutiny.
In this study, TPF90 cycles were administered at a me-
dian interval of 23 days from each other (range:
20e31 days), and the dose intensity was 82% of the original
TPF regimen. The dose intensity of cisplatin can have an
impact on the clinical outcomes of HNSCC patients under-
going CCRT.21,22 However, the question as to whether the
dose intensity of ICT TPF can affect the therapeutic results
remains open. Despite using an ICT TPF regimen with a
lower dose intensity, the CR and PR rates observed in our
intention-to-treat population (13.5% and 59.6%, respec-
tively) were similar to those reported in the TAX 323 trial
(8.5% and 59.3%, respectively).
In general, disease control is largely dependent on an
effective post-ICT locoregional therapy (mainly RT or CCRT
for unresectable HNSCC). However, a substantial proportion
of patients with unresectable disease did not receive RT in
the current study (mainly because of disease progression or
the onset of ICT TPF-related adverse events). It is none-
theless worth noting that only 15.4% of our patients were
not treated with RT, a substantially lower proportion than
those reported (27e31%) in previous ICT TPF trials con-
ducted in patients with unresectable HNSCC.2,23
The CT regimen used for post-ICT CCRT is another crit-
ical determinant of outcomes in patients with advanced
HNSCC. In the current study, weekly cisplatin 40 mg/m2 was
used in combination with RT (a commonly used alternative
to 3-weekly cisplatin 100 mg/m2 in Asian countries).24 Using
weekly cisplatin 40 mg/m2, the major Grade 3e4 adversePlease cite this article in press as: Wang H-M, et al., Induction chemot
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postsurgery adjuvant setting were as follows: neutropenia
29% versus 12%, anemia 30% versus 9%, stomatitis 78% versus
67%, and dermatitis 15% versus 6%.25 These data suggest
that ICT TPF may increase the severity of adverse events of
the following CCRT. Although previous studies utilized
different approaches (i.e., RT alone, CCRT with various CT
regimens, and bioradiotherapy with cetuximab),2,5,6,17,26,27
the optimal strategy for minimizing treatment-related
morbidity has not been yet identified.
Herein, the estimated 3-year OS and PFS rates were 41%
and 23%, respectively (Figures 1 and 2), with the median OS
and PFS durations being 21.0 months and 16.0 months,
respectively. The ICT TPF arm included in the TAX 323 trial
showed an OS rate of 37% and a median OS of 18.8 months.2
Moreover, the Spanish Head and Neck Cancer Cooperative
Group (TTCC) trial reported median OS and PFS durations of
27.0 months and 14.6 months, respectively.23 The different
number and characteristics of the study patients may, at
least in part, explain the observed differences in survival
rates. In the current study, 13.5% of patients who under-
went ICT TPF were surgically salvaged. The use of salvage
surgery in the TAX 323 and TTCC trials was 15.3% and 27.1%,
respectively, suggesting important differences in the study
participants. A previous Taiwanese retrospective study
conducted in patients with unresectable tumors or candi-
dates for organ preservation who were treated with ICT at a
dose similar to TPF80 reported a median PFS of 435 days.
12
Twenty-three (44%) of our patients had oropharyngeal
cancer. Twelve patients were examined for p16 expression
by immunohistochemistry, and three (25%) of them had
strong diffuse nuclear and cytoplasmic immunohistochem-
istry staining of p16 in more than 70% of tumor cells. Such
patients were considered to have human papillomavirus
(HPV)-related HNSCC.28 No positive p16 staining was
observed in the remaining nine patients. The three HPV-
positive patients had T4 disease, ultimately being at high
risk according to the refined American Joint Committee on
Cancer criteria for HPV-related oropharyngeal squamous
cell carcinoma.29 All of them died of disease with an OS of
4 months, 8 months, and 21 months. In Taiwan, the inci-
dence of HPV-related site HNSCC (1.3/100,000 in 1995 to
3.3/100,000 in 2009, annual percentage change 56.9,
p < 0.0001) has increased more rapidly than that of HPV-
unrelated site HNSCC (10.4/100,000 in 1995 to 21.7/
100,000 in 2009, annual percentage change 55.0,
p < 0.0001).30 However, the HPV-positive rates in Taiwan
(13e17%) remain significantly lower than those reported in
industrialized countries.31,32 In this context, optimization
of intensive therapeutic approaches with an acceptable
burden of adverse events is paramount, especially for HPV-
unrelated HNSCC patients.
In conclusion, our experience indicates that TPF90 is a
suitable option for Asian patients with borderline resect-
able or unresectable HNSCC who are scheduled for ICT TPF.
Despite the reduced dosage, such an approach allowed us
to achieve survival figures similar to those reported for the
original dose regimen. However, we acknowledge the
shortcomings of our report. The dose reduction to 90% was
not through a Phase I study and was chosen in accordance
with the adverse events in a small number of patients. Can
a dose reduction of more than 10% further reduce theherapy with dose-modified docetaxel, cisplatin, and 5-fluorouracil
neck cancer, Journal of the Formosan Medical Association (2016),
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+ MODELadverse effects and have a comparative efficacy? Future
studies aiming at both identifying the ideal candidates for
ICT TPF and optimizing the balance between its efficacy
and toxicity are needed.Acknowledgments
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